93 results
8-K
EX-99.1
MIRM
Mirum Pharmaceuticals Inc
8 May 24
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
4:04pm
.
IMPORTANT SAFETY INFORMATION
Limitation of Use: LIVMARLI is not for use in PFIC type 2 patients who have a severe defect in the bile salt export pump … OF USE
The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to single enzyme defects
8-K
EX-99.1
35yd49
28 Feb 24
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
4:05pm
8-K
EX-99.1
dttrp4
8 Jan 24
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
8:30am
8-K
EX-99.2
l6b5uectrhza
8 Jan 24
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
8:30am
8-K
n5u146 vhv1o2j
18 Dec 23
Other Events
4:06pm
424B5
rchb2a7f 0eaq1
2 Nov 23
Prospectus supplement for primary offering
4:59pm
8-K
EX-99.1
brudizp
2 Nov 23
Results of Operations and Financial Condition
4:06pm
S-3ASR
q2rwrad070xym
13 Oct 23
Automatic shelf registration
4:47pm
8-K
EX-99.1
yaycnnvl1u 3fbor
13 Oct 23
Other Events
4:16pm
8-K
EX-99.1
fthtdbxv19lxwuo91n6
5 Sep 23
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
8:36am
8-K
EX-99.1
yp1nhuq3v1m yeji6jo
3 Aug 23
Results of Operations and Financial Condition
4:05pm
8-K
EX-2.1
82880mwz38caei56
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
8-K
EX-99.1
nja0uw6
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am